Patents by Inventor James E. Kipp
James E. Kipp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9044381Abstract: The present invention is concerned with delivering a pharmaceutical composition to the brain of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the brain of a portion of the pharmaceutical composition by cells capable of reaching the brain. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytized or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the brain.Type: GrantFiled: June 15, 2004Date of Patent: June 2, 2015Assignees: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SA, Board of Regents of the University of Nebraska by and Behalf of the University of Nebraska Medical CenterInventors: Barrett Rabinow, James E. Kipp, Howard Gendelman
-
Patent number: 8986736Abstract: The present invention is concerned with delivering a pharmaceutical composition to a tissue target of a mammalian subject for treating brain diseases or disorders. The process includes the steps of: (i) providing a dispersion of the pharmaceutical composition as particles having an average particle size of from about 150 nm to about 100 microns, and (ii) administering the dispersion to the mammalian subject for delivery to the tissue target of a portion of the pharmaceutical composition by cells capable of reaching the tissue target. The dispersion of the pharmaceutical composition as particles, for example, can be phagocytized or adsorbed by the cells prior or subsequent to administration into the mammalian subject. The dispersion of the pharmaceutical composition can be administered to the central nervous system or the vascular system. After administration, the loaded cells transport the pharmaceutical composition as particles into the tissue target.Type: GrantFiled: April 19, 2006Date of Patent: March 24, 2015Assignees: Baxter International Inc., Baxter Healthcare SA, Board of Regents of the University of NebraskaInventors: Barrett E. Rabinow, Howard E. Gendelman, James E. Kipp
-
Publication number: 20140212495Abstract: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.Type: ApplicationFiled: August 15, 2013Publication date: July 31, 2014Applicant: ZIOPHARM ONCOLOGY, INC.Inventors: Pavlos Papadopoulos, Gerhard Raab, Mark J. Doty, James E. Kipp, Berthold Roessler
-
Patent number: 8722091Abstract: The present invention relates to a process for preparing submicron sized nanoparticles of a poorly water soluble compound by lyophilizing a dispersion or microdispersion of a multiphase system having an organic phase and an aqueous phase, the organic phase having the poorly water soluble organic compound therein. The method is preferably used to prepare nanoparticles of a poorly water soluble, pharmaceutically active compound suitable for in vivo delivery, particularly by parenteral routes.Type: GrantFiled: August 17, 2004Date of Patent: May 13, 2014Assignee: Baxter International Inc.Inventors: Sean Brynjelsen, Mark Doty, James E. Kipp, Nailesh Jayswal, Krishnaswamy Narayanan
-
Patent number: 8333959Abstract: The present invention is concerned with a method of preparing and delivering small particles of a pharmaceutically active material to a mammalian subject for treating diseases or disorders.Type: GrantFiled: June 9, 2005Date of Patent: December 18, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A., Board of Regents of the University of Nebraska by and Behalf of the University of Nebraska Medical CenterInventors: James E. Kipp, Barrett E. Rabinow
-
Patent number: 8263131Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 ?m as measured by laser diffractometry.Type: GrantFiled: March 30, 2009Date of Patent: September 11, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Barrett Rabinow, Randy White, Chong-Son Sun, Joseph Chung Take Wong, James E. Kipp, Mark Doty, Christine L. Rebbeck, Pavlos Papadopoulos
-
Publication number: 20120207762Abstract: Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The aqueous pharmaceutical solution can be cooled to a temperature of about ?50° C. to about ?10° C. The vitrifying additive enhances the formation of a glass or amorphous solid of the aqueous pharmaceutical solution at cryogenic temperatures (?50 to ?10° C.), and the pharmaceutical formulation can be thawed to liquid form and administered to a mammalian subject.Type: ApplicationFiled: April 23, 2012Publication date: August 16, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Lakshmy Nair, Reagan Miller, Barrett E. Rabinow
-
Patent number: 8183233Abstract: Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The aqueous pharmaceutical solution can be cooled to a temperature of about ?50° C. to about ?10° C. The vitrifying additive enhances the formation of a glass or amorphous solid of the aqueous pharmaceutical solution at cryogenic temperatures (?50 to ?10° C.), and the pharmaceutical formulation can be thawed to liquid form and administered to a mammalian subject.Type: GrantFiled: May 8, 2009Date of Patent: May 22, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: James E. Kipp, Joseph Chung Tak Wong, Lakshmy Nair, Reagan Miller, Barrett E. Rabinow
-
Patent number: 7776360Abstract: The present invention is directed to novel compounds, methods of manufacture and methods of use. The present invention is also directed to solid drug/active agent particles having one or more of the compounds of the present invention associated with the surface thereof. The compounds of the present invention are comprised of a non-polar polyether covalently linked to an anionic sulfonate group. The compounds have an amphipathic quality and preferably, are surface active. Such compounds are preferably useful as surface-active agents to coat and stabilize dispersions of particles in a continuous liquid medium. These surface-active agents may be applied in the stabilization of suspensions, emulsions, or liposome formulations intended for pharmaceutical, medical, cosmetic, or agricultural use. The particles that can be prepared by a variety of methods and will preferably comprise a pharmaceutical agent.Type: GrantFiled: December 15, 2005Date of Patent: August 17, 2010Assignees: Baxter International, Baxter Healthcare S.A.Inventors: James E. Kipp, Ton That Hai, Bennett P. Melnick
-
Publication number: 20100086611Abstract: The present invention relates to compositions of submicron- to micron-size particles of antimicrobial agents. More particularly the invention relates to a composition of an antimicrobial agent that renders the agent potent against organisms normally considered to be resistant to the agent. The composition comprises an aqueous suspension of submicron- to micron-size particles containing the agent coated with at least one surfactant selected from the group consisting of: ionic surfactants, non-ionic surfactants, biologically derived surfactants, and amino acids and their derivatives. The particles have a volume-weighted mean particle size of less than 5 ?m as measured by laser diffractometry.Type: ApplicationFiled: March 30, 2009Publication date: April 8, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Barrett Rabinow, Randy White, Chong-Son Sun, Joseph Chung Tak Wong, James E. Kipp, Mark J. Doty, Christine Rebbeck, Pavlos George Papadopoulos
-
Publication number: 20090286764Abstract: Stable pharmaceutical formulations and methods of making same are provided. In a general embodiment, the present disclosure provides a method of making a stable pharmaceutical formulation comprising adding one or more vitrifying additives to an aqueous pharmaceutical solution to raise the glass transition temperature of the aqueous pharmaceutical solution. The aqueous pharmaceutical solution can be cooled to a temperature of about ?50° C. to about ?10° C. The vitrifying additive enhances the formation of a glass or amorphous solid of the aqueous pharmaceutical solution at cryogenic temperatures (?50 to ?10° C.), and the pharmaceutical formulation can be thawed to liquid form and administered to a mammalian subject.Type: ApplicationFiled: May 8, 2009Publication date: November 19, 2009Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: JAMES E. KIPP, JOSEPH CHUNG TAK WONG, LAKSHMY NAIR, REAGAN MILLER, BARRETT E. RABINOW
-
Publication number: 20090152176Abstract: The disclosure describes apparatuses and methods of use that may be used to remove material with magnetic properties from compositions, particularly pharmaceutical compositions. The apparatuses provide a conduit or column in which a magnetic field exists and through which a composition flows. Magnetic material in the composition is substantially reduced after flowing through the conduit or column.Type: ApplicationFiled: December 21, 2007Publication date: June 18, 2009Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: James E. Kipp, Joseph Chung Tak Wong, Jane O. Werling
-
Patent number: 7511079Abstract: Methods and apparatuses for comminuting and stabilizing small particles are provided. In one embodiment, an apparatus moves an organic compound dissolved in a solvent to form a suspension of particles in a first fluid stream and moves the suspension in a second fluid stream, wherein the second fluid stream is oriented and positioned with respect to the first stream to cause shearing between the streams and mixing of at least some of the particles in the first and second streams.Type: GrantFiled: March 22, 2004Date of Patent: March 31, 2009Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Monte Wisler, Rhonda Garcia
-
Patent number: 7193084Abstract: The present invention provides a polymorphic form of itraconazole.Type: GrantFiled: August 5, 2002Date of Patent: March 20, 2007Assignee: Baxter International Inc.Inventors: Jane Werling, Mark J. Doty, Christine L. Rebbeck, Joseph Chung Tak Wong, James E. Kipp
-
Patent number: 7112340Abstract: The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of time, preferably six months or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration.Type: GrantFiled: October 11, 2002Date of Patent: September 26, 2006Assignee: Baxter International Inc.Inventors: James E. Kipp, Mark J. Doty, Christine L. Rebbeck, Sean Brynjelsen, Jamie Teresa Konkel
-
Patent number: 7067143Abstract: A premix parenteral solution for intravenous administration having amiodarone, as an active ingredient, solubilized in a solution of water for injection and about 0.4-12 mg/ml of a non-ionic surfactant to a concentration range of from 0.2 to 6 mg/ml is disclosed. The solution optionally may include an osmotic agent. No dilution of the solution is required before administering to a patient and the sterile packaged solution has an initial pH within the range of from about 2.9 to about 3.2, preferably about 3.1. Additionally, a method for producing an amiodarone solution suitable for intravenous administration is further disclosed.Type: GrantFiled: August 31, 2001Date of Patent: June 27, 2006Assignee: Baxter International, Inc.Inventors: Mark J. Doty, Christine L. Rebbeck, James E. Kipp, Neervalur V. Raghavan
-
Patent number: 7037528Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of 400 nm to 2 microns.Type: GrantFiled: June 5, 2001Date of Patent: May 2, 2006Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck
-
Patent number: 6977085Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of: (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound; and (iii) seeding the first solution or the second solvent or the pre-suspension.Type: GrantFiled: October 19, 2001Date of Patent: December 20, 2005Assignee: Baxter International Inc.Inventors: Jane Werling, James E. Kipp, Rajaram Sriram, Mark J. Doty
-
Patent number: 6951656Abstract: The present invention provides a method for preparing submicron sized particles of an organic compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous, the process including the steps of: (i) dissolving the organic compound in the water-miscible first solvent to form a solution, (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of less than about 2 ?m.Type: GrantFiled: September 17, 2001Date of Patent: October 4, 2005Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Christine L. Rebbeck, Sean Brynjelsen
-
Patent number: 6884436Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of: (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound; and (iii) seeding the first solution or the second solvent or the pre-suspension.Type: GrantFiled: December 12, 2001Date of Patent: April 26, 2005Assignee: Baxter International Inc.Inventors: James E. Kipp, Joseph Chung Tak Wong, Mark J. Doty, Jane Werling, Christine L. Rebbeck, Sean Brynjelsen